Clinical Trial Update: The Efficacy and Safety of JAK Inhibitor in the Treatment of Anti-MDA5 Antibody-positive Dermatomyositis Patients [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating a JAK inhibitor for adult Dermatomyositis with anti-MDA5 antibodies, focusing on efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatomyositis

Drugs mentioned

• JAK inhibitor

Snippet

Sponsor: First Affiliated Hospital Xi'an Jiaotong University | Conditions: Dermatomyositis, Adult Type | Phase 4 | Status: UNKNOWN